Biomarker ID | 283 |
PMID | 18543251 |
Year | 2008 |
Biomarker | Myosin VI (MYO6) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- Gap junction degradation,Gap junction trafficking and regulation, Glutamate binding and activation of AMPA receptors and synaptic plasticity,Membran trafficking,Transmission across chemical synapses |
Experiment | Tumor and adjacent normal prostate tissues |
Type of Biomarker | Diagnostic |
Cohort | 15 patients having radical prosteactomies were chosen for the study. Tumor and adjacent normal prostate tissues were analysed. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | NA |
Method Used | Immunohistochemical |
Clinical | No |
Remarks | Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | MYO6 |